While the hub of the consortium is at UC Davis, the group includes investigators at Erasmus Medical Center, Rotterdam, the Netherlands; the University of Washington, Seattle; the University of Colorado Health Sciences Center, Denver; and Scripps Research Institute, Florida. All research sites will share the common objectives of developing therapeutic interventions and quantitative means for assessing their efficacy.
The award underscores the growing commitment at the NIH to disorders related to the Fragile X gene. The current award will be administered across four institutes: the National Center for Research Resources (NCRR), the National Institute on Aging (NIA), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute on Drug Abuse (NIDA).
The research projects will use state-of-the-art measures to both assess features of the clinical presentation of FXTAS and to study FXS. The development of novel transgenic mouse models to evaluate candidate therapeutic drugs and the potential for reversing the neurodegenerative process will be a particular focus of the consortium.
A postdoctoral training component will enhance the power of the consortium through education of postdoctoral trainees in translational (bench-to-bedside) research. The experience provided to the postdoctoral scholars will be a unique opportunity to advance translational research in the broader Fragile X field, thereby creating a new generation of talented Fragile X researchers.
A unique feature of the consortium is its Community Advisory Board
(CAB). This board will connect the consortium to those who stand to benefit
from its efforts. "Families affected by one of the Fragile X-related
disorders provide the most powerful motivating force for translational
research," says Robert Miller, a CAB member and executive director of the
NFXF. "They deserve to have both a voice in support of research efforts,
and a means of monito
|SOURCE The National Fragile X Foundation|
Copyright©2007 PR Newswire.
All rights reserved